Skip to main content
. 2018 Apr 20;7(8):e1452581. doi: 10.1080/2162402X.2018.1452581

Table 3.

Multivariate analysis (Cox Model) on progression-free survival.

Variable Hazard ratio (HR) IC 95% p-value
PS > 1 4.85 1.28–18.35 0.020
sPD-L1 at first tumor evaluation (continuous variable) 0.99 0.97–1.01 0.467
sGranzyme B at nivolumab initiation (continuous variable) 0.99 0.94–1.04 0.628
Increase of sPD-L1 concentrations 4.85 1.02-NR 0.048
Increase sGranzyme B concentrations 1.82 0.61–5.43 0.284
IHC PD-L1 positive 0.79 0.26–2.42 0.681